Real-world effectiveness of third-line cabazitaxel in patients with metastatic castration-resistant prostate cancer: CARD-like analysis of data from a post-marketing surveillance in Japan

Peer Review reports

Original Submission
19 Jul 2022	Submitted	Original manuscript
Resubmission - Version 2
	Submitted	Manuscript version 2
Resubmission - Version 3
	Submitted	Manuscript version 3
Resubmission - Version 4
	Submitted	Manuscript version 4
10 Feb 2023	Reviewed	Reviewer Report
17 Feb 2023	Reviewed	Reviewer Report - Masashi Morita
12 May 2023	Author responded	Author comments - Hideyasu Matsuyama
Resubmission - Version 5
12 May 2023	Submitted	Manuscript version 5
16 May 2023	Reviewed	Reviewer Report
22 May 2023	Reviewed	Reviewer Report - Masashi Morita
Resubmission - Version 6
	Submitted	Manuscript version 6
Publishing
23 May 2023	Editorially accepted
13 Jun 2023	Article published	10.1186/s12885-023-10998-w

Back to article page